Groundbreaking GLP-1 implant trial offers hope for diabetic and obese cats
Okava Pharmaceuticals, led by founder and CEO Michael Klotsman, is developing an injectable implant called OKV-119. Unlike human GLP-1 drugs that require weekly injections, this implant releases medication for up to six months. The company aims to seek FDA approval between 2027 and 2028.
If successful, the drug could transform care for millions of obese and diabetic pets. Developers must still address financial and practical hurdles before it reaches the veterinary market. The outcome of the study will determine whether the treatment becomes a viable option for pet owners.
